Mobile
+201227693377 - +201227693388 -
+202 22673175
Address
Secondary Trade Building Entrance No. 5, Fifth Area- Sheraton Heliopolis, Cairo.

Uric pure 300 mg

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 
  • Pack

30 tablets

  • Composition

Each tablet contains:

Allopurinol                                   300 mg

  • Indication

Uric Pure is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase.

Uric Pure is indicated for the management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase.

Uric Pure is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Contact Us

Secondary Trade Building Entrance No. 5, Fifth Area- Sheraton Heliopolis, Cairo.
Phone : 00201227693377 - 00201227693388 00202 22673175 - 00202 22673176
Fax : 00202 22674934
Email : Mepaco@mepaco–pharma.net
© Copyright 2022 MEPACO MEDIFOOD. All Rights Reserved. Powered by Fine Arts